GoodRx, a leading U.

S. prescription savings platform, has announced a new collaboration with global healthcare company Viatris to reduce the cost of 17 established brand medications for consumers, offering savings for both commercially insured and cash-paying patients.

Beginning immediately, commercially insured patients who are eligible may pay as low as $0 to $4 for select Viatris medications when utilizing the GoodRx platform. For cash-paying consumers, regardless of their insurance status, GoodRx provides access to discounted cash prices, potentially saving them up to 85% off at over 70,000 pharmacies nationwide. The program includes widely recognized medications such as Lipitor®, Celebrex®, Viagra®, and Norvasc®.

Laura Jensen, Chief Commercial Officer and President of Pharma Direct at GoodRx, emphasized the importance of ensuring medication access. “Affordability should never be the reason someone walks away without their medication,” Jensen stated. She added that Viatris’s initiative to provide substantial savings for branded medication users demonstrates a clear commitment to improving patient access, and connecting these savings to a trusted platform like GoodRx expands access and supports adherence across the U.

S.

Many of the Viatris medications included in this program already show significant search volume on GoodRx, indicating consumers’ consistent efforts to find reliable cost information. Integrating these savings directly onto the GoodRx platform aims to help Americans overcome financial barriers that often influence whether prescriptions are filled.

Corinne Le Goff, Chief Commercial Officer at Viatris, commented on the partnership’s strategic value. “At Viatris, we’re focused on delivering solutions that are effective at scale. Our established brands already serve millions of patients, and this partnership with GoodRx creates another opportunity for patients to access these widely recognized medicines,” Le Goff said. She highlighted that expanding access pathways through trusted platforms like GoodRx is crucial for keeping essential medicines within reach as healthcare evolves.

The collaboration underscores GoodRx’s role in operationalizing complex direct-to-consumer and manufacturer-sponsored programs across various insurance types, particularly for established brands. By integrating manufacturer pricing into a consumer experience used by nearly 25 million Americans annually, GoodRx assists brands in remaining competitive, visible, and accessible to patients. GoodRx’s existing portfolio of manufacturer programs includes Dexcom G7, Humira® biosimilar ADBM, Lantus®, Ozempic®, and Wegovy®, illustrating its capability to streamline affordability and achieve national reach. GoodRx has helped Americans save over $100 billion on medication costs since 2011.